Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial

Justin P Turner, Patricia Caetano, Cara Tannenbaum, Justin P Turner, Patricia Caetano, Cara Tannenbaum

Abstract

Background: Opioid use has risen to epidemic proportions across Canada, with increasing evidence of harms including accidental overdose and death. Policy-makers have called for effective approaches to promote opioid reduction. One promising method from deprescribing randomized trials is to empower patients through direct-to-patient education. The current trial will evaluate the effectiveness of a government-led mail-out of educational information to adult community-dwelling, chronic opioid users on the reduction of opioids compared to usual care.

Methods: This is a pragmatic, prospective, cluster randomized, parallel-arm controlled trial, comparing mailed distribution of a direct-to-patient educational brochure for chronic opioid use (intervention arm) to usual care (control arm). Eligible participants from across Manitoba, Canada, will be identified by the Provincial Drug Programs Branch within the Manitoba Health, Seniors and Active Living Department of the Manitoba Government, allocated to primary care providers, and the latter will be randomized in clusters of family medicine practices to achieve a 1:1 ratio. The primary outcome is complete cessation of opioids after 6 months assessed using Drug Program Information Network data. Secondary outcomes include ≥ 25% dose reduction in the mean morphine milligram equivalent (MME) daily dose, reduction of daily dose to < 90 mg MME, or therapeutic switch to another opioid or non-opioid medication. Data will be analyzed using intent-to-treat generalized estimating equations.

Discussion: This trial will test the efficacy of a population-based, wide-scale, government-led direct-to-patient educational initiative to drive reductions in chronic opioid use by community-dwelling adults across Manitoba.

Trial registration: ClinicalTrials.gov, ID: NCT03400384 . Registered on 18 January 2018.

Keywords: Analgesics; Chronic pain; Deprescribing; Government; Opioids; Patient education; Policy.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A flow chart for the study process
Fig. 2
Fig. 2
Schedule of enrollment, intervention and assessment

References

    1. American Pain Society and American Academy of Pain Medicine . Guideline for the use of chronic opioid therapy in chronic noncancer pain: evidence review. 2009.
    1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130. doi: 10.1016/j.jpain.2008.10.008.
    1. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–286. doi: 10.7326/M14-2559.
    1. Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25(4):310–315. doi: 10.1007/s11606-009-1218-z.
    1. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59(3):430–438. doi: 10.1111/j.1532-5415.2011.03318.x.
    1. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Am J Epidemiol. 2013;178(4):559–569. doi: 10.1093/aje/kwt013.
    1. Carman WJ, Su S, Cook SF, Wurzelmann JI, McAfee A. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011;20(7):754–762. doi: 10.1002/pds.2131.
    1. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013;273(5):511–526. doi: 10.1111/joim.12035.
    1. Deyo RA, Smith DH, Johnson ES, Tillotson CJ, Donovan M, Yang X, et al. Prescription opioids for back pain and use of medications for erectile dysfunction. Spine (Phila Pa 1976) 2013;38(11):909–915. doi: 10.1097/BRS.0b013e3182830482.
    1. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med. 2013;173(3):196–201. doi: 10.1001/2013.jamainternmed.733.
    1. Canadian Institute for Health Information Canadian Centre on Substance Abuse . Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa: CIHI; 2016.
    1. Canadian Institute for Health Information . Opioid-related harms in Canada. Ottawa: CIHI; 2017.
    1. Health Canada . Government of Canada Actions on Opioids 2016 and 2017. Ottawa: Health Canada; 2017.
    1. Canadian Institute for Health Information . Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. Ottawa: CIHI; 2017.
    1. Health Canada. National report: apparent opioid-related deaths (2016). Ottawa: Health Canada; 2017.
    1. Transort Canada . Canadian motor vehicle traffic collision statistics. 2015.
    1. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to December 2017). Web-based report. Ottawa: Public Health Agency of Canada; 2018. . Accessed 01 Sept 2018.
    1. Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207. doi: 10.1136/bmj.k3207.
    1. McNutt LA, Coles FB, McAuliffe T, Baird S, Morse DL, Strogatz DS, et al. Impact of regulation on benzodiazepine prescribing to a low income elderly population, New York State. J Clin Epidemiol. 1994;47(6):613–625. doi: 10.1016/0895-4356(94)90209-7.
    1. Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff (Millwood) 2017;36(4):733–741. doi: 10.1377/hlthaff.2016.1141.
    1. Morin KA, Eibl JK, Franklyn AM, Marsh DC. The opioid crisis: past, present and future policy climate in Ontario, Canada. Subst Abuse Treat Prev Policy. 2017;12(1):45. doi: 10.1186/s13011-017-0130-5.
    1. Schaffer AL, Buckley NA, Cairns R, Pearson SA. Interrupted time series analysis of the effect of rescheduling alprazolam in Australia: taking control of prescription drug use. JAMA Intern Med. 2016;176(8):1223–1225. doi: 10.1001/jamainternmed.2016.2992.
    1. Lloyd B, Dwyer J, Bugeja L, Jamieson A. Alprazolam in fatal overdose following regulatory rescheduling: a response to Deacon et al. Int J Drug Policy. 2017;39:138–139. doi: 10.1016/j.drugpo.2016.10.008.
    1. Hedegaard H, Chen LH, Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief. 2015;190:1–8.
    1. Dollman WB, Leblanc VT, Stevens L, O'Connor PJ, Roughead EE, Gilbert AL. Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. J Clin Pharm Ther. 2005;30(5):425–432. doi: 10.1111/j.1365-2710.2005.00674.x.
    1. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. doi: 10.1001/jamainternmed.2014.949.
    1. Tannenbaum C, Farrell B, Shaw J, Morgan S, Trimble J, Currie J, et al. An ecological approach to reducing potentially inappropriate medication use: Canadian Deprescribing Network. Can J Aging. 2017;36(1):97–107. doi: 10.1017/S0714980816000702.
    1. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2019. Oslo. Oslo; 2018. Available at .
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Martin P, Tamblyn R, Ahmed S, Benedetti A, Tannenbaum C. A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial. Trials. 2015;16(1):266. doi: 10.1186/s13063-015-0791-1.
    1. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: The D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889–1898. doi: 10.1001/jama.2018.16131.
    1. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–EE66. doi: 10.1503/cmaj.170363.
    1. Goodman CW, Brett AS. Gabapentin and pregabalin for pain—Is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411–414. doi: 10.1056/NEJMp1704633.
    1. Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol. 2006;35(5):1292–1300. doi: 10.1093/ije/dyl129.
    1. Thompson DM, Fernald DH, Mold JW. Intraclass correlation coefficients typical of cluster-randomized studies: estimates from the Robert Wood Johnson Prescription for Health Projects. Ann Fam Med. 2012;10(3):235–240. doi: 10.1370/afm.1347.
    1. Morgan SG, Hunt J, Rioux J, Proulx J, Weymann D, Tannenbaum C. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ Open. 2016;4(2):E346–E351. doi: 10.9778/cmajo.20150131.
    1. Nadelmann E, LaSalle L. Two steps forward, one step back: current harm reduction policy and politics in the United States. Harm Reduct J. 2017;14(1):37. doi: 10.1186/s12954-017-0157-y.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren